CD209 Signaling Pathway As a Biomarker for Cisplatin Chemotherapy Response in Small Cell Lung Cancer

Overview

Journal Genes Dis

Date 2024 Jan 26

PMID 38274378

Authors

Anqi Lin

Hong Yang

Jian Zhang

Peng Luo

Affiliations

Soon will be listed here.

Citing Articles

Comprehensive investigation of tumor immune microenvironment and prognostic biomarkers in osteosarcoma through integrated bulk and single-cell transcriptomic analysis.

Shi S, Zhang L, Guo X Front Immunol. 2024; 15:1424950.

PMID: 39108264 PMC: 11300251. DOI: 10.3389/fimmu.2024.1424950.

The Construction of a Multi-Gene Risk Model for Colon Cancer Prognosis and Drug Treatments Prediction.

Gao L, Tian Y, Chen E Int J Mol Sci. 2024; 25(7).

PMID: 38612764 PMC: 11011764. DOI: 10.3390/ijms25073954.

References

Chen P, Kuang P, Wang L, Li W, Chen B, Liu Y . Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure. Transl Lung Cancer Res. 2020; 9(3):768-786. PMC: 7354133. DOI: 10.21037/tlcr-19-547. View

Li J, Chen S, Li Y, Zhu Z, Huang H, Wang W . Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2. Front Genet. 2022; 13:883234. PMC: 9247358. DOI: 10.3389/fgene.2022.883234. View

George J, Lim J, Jang S, Cun Y, Ozretic L, Kong G . Comprehensive genomic profiles of small cell lung cancer. Nature. 2015; 524(7563):47-53. PMC: 4861069. DOI: 10.1038/nature14664. View

Wu L, Wang X, He X, Li Q, Hua Q, Liu R . MMP9 Expression Correlates With Cisplatin Resistance in Small Cell Lung Cancer Patients. Front Pharmacol. 2022; 13:868203. PMC: 9010875. DOI: 10.3389/fphar.2022.868203. View

Kremsreiter S, Kroell A, Weinberger K, Boehm H . Glycan-Lectin Interactions in Cancer and Viral Infections and How to Disrupt Them. Int J Mol Sci. 2021; 22(19). PMC: 8508825. DOI: 10.3390/ijms221910577. View